Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Leukemia|November 9, 2022
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphomaWendan Xu, Philipp Berning, Tabea Erdmann, et al.Molecular Cancer Therapeutics|August 12, 2018
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null TumorsJames T Lynch, Urszula M Polanska, Ursula Hancox, et al.Cancer Cell|April 3, 2012
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cellsWilliam J Harris, Xu Huang, James T Lynch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null TumorsJames T Lynch, Urszula M Polanska, Oona Delpuech, et al.Oncogene|October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitorsShanade Dunn, Cath Eberlein, Jason Yu, et al.Cell Reports|March 29, 2018
Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid LeukemiaAlba Maiques-Diaz, Gary J Spencer, James T Lynch, et al.Communications Biology|February 5, 2025
Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancerBengul Gokbayrak, Umut Berkay Altintas, Shreyas Lingadahalli, et al.Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.Blood|February 17, 2017
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCLTabea Erdmann, Pavel Klener, James T Lynch, et al.Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.Pageof 3